23 results
Thumbnail

D1.418 - An EBP Gene Variant in a Child with Immunodeficiency: A Case from the Chondrodysplasia Pontata Spectrum

Thumbnail

D1.419 - The management of Immunological Diseases in Internal Medicine Departments

Thumbnail

D1.404 - Live Renal Transplantation Outcome in Egyptian Cohort: A Single Center Study

Thumbnail

D1.405 - Establishment of a Mouse Nasal Epithelial Cell Air–Liquid Interface Culture System and Its Application in Mucosal Barrier Research

Thumbnail

D1.407 - Real-world patient characterization, prior long-term prophylactic prescribing patterns, and treatment outcomes for adults on berotralstat with hereditary angioedema in Japan

Thumbnail

D1.413 - A Novel Variant of CORO1A Gene Contributing to The Development of Primary Immunodeficiency in Children

Thumbnail

D1.415 - Regulatory T‑Cell Deficiency and NF‑κB/IL‑1β Activation in Dilated Cardiomyopathy

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis